Cargando…

Low Lymphocytes and IFN-Neutralizing Autoantibodies as Biomarkers of COVID-19 Mortality

Detalles Bibliográficos
Autores principales:	Troya, Jesús, Bastard, Paul, Casanova, Jean-Laurent, Abel, Laurent, Pujol, Aurora
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893354/ https://www.ncbi.nlm.nih.gov/pubmed/35243564 http://dx.doi.org/10.1007/s10875-022-01241-5

Ejemplares similares

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain
por: Troya, Jesús, et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Interferon-β Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2
por: Bastard, Paul, et al.
Publicado: (2021)

Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma
por: Vazquez, Sara E., et al.
Publicado: (2021)

No increased prevalence of autoantibodies neutralizing type I IFNs in idiopathic pulmonary fibrosis patients
por: Philippot, Quentin, et al.
Publicado: (2023)

IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2
por: Lévy, Romain, et al.
Publicado: (2021)

Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
por: Borsani, Oscar, et al.
Publicado: (2022)

Autoantibodies against type I interferons are associated with multi-organ failure in COVID-19 patients
por: Koning, Rutger, et al.
Publicado: (2021)

Human autoantibodies underlying infectious diseases
por: Puel, Anne, et al.
Publicado: (2022)

Autoantibodies neutralizing type I interferons in 20% of COVID-19 deaths in a French hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2021)

Autoantibodies Neutralizing Type I Interferons in 20% of COVID-19 Deaths in a French Hospital
por: Chauvineau-Grenier, Angélique, et al.
Publicado: (2022)

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β
por: Vinh, Donald C., et al.
Publicado: (2021)

Autoantibodies Against Type I IFNs in Patients with Ph-Negative Myeloproliferative Neoplasms
por: Borsani, Oscar, et al.
Publicado: (2021)

Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients
por: Gervais, Adrian, et al.
Publicado: (2023)

Autoantibodies Neutralizing Type I IFNs in the Bronchoalveolar Lavage of at Least 10% of Patients During Life-Threatening COVID-19 Pneumonia
por: Philippot, Quentin, et al.
Publicado: (2023)

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
por: Lopez, Jonathan, et al.
Publicado: (2021)

Neutralizing Anti-interferon-γ Autoantibodies: an Ameliorating Factor in COVID-19 Infection?
por: Kacar, Mark, et al.
Publicado: (2021)

Paraneoplastic pemphigus with anti-desmocollin 3 autoantibodies and chronic lymphocytic leukemia
por: Adaszewska, Alicja, et al.
Publicado: (2018)

Correction: Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs
por: Lopez, Jonathan, et al.
Publicado: (2021)

Type I IFN immunoprofiling in COVID-19 patients
por: Trouillet-Assant, Sophie, et al.
Publicado: (2020)

Autoantibodies against type I IFNs in patients with critical influenza pneumonia
por: Zhang, Qian, et al.
Publicado: (2022)

Anti-GM-CSF Neutralizing Autoantibodies in Colombian Patients with Disseminated Cryptococcosis
por: Arango-Franco, Carlos A., et al.
Publicado: (2023)

Functional neutralization of anti-IFN-γ autoantibody in patients with nontuberculous mycobacteria infection
por: Krisnawati, Dyah Ika, et al.
Publicado: (2019)

Correction to: IFN-α2a Therapy in Two Patients with Inborn Errors of TLR3 and IRF3 Infected with SARS-CoV-2
por: Lévy, Romain, et al.
Publicado: (2021)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients With Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Neutralizing Type I Interferon Autoantibodies in Japanese Patients with Severe COVID-19
por: Eto, Shohei, et al.
Publicado: (2022)

Differential regulation of IFNα, IFNβ and IFNε gene expression in human cervical epithelial cells
por: Couret, Jennifer, et al.
Publicado: (2017)

IFN-γ Mediates the Rejection of Haematopoietic Stem Cells in IFN-γR1-Deficient Hosts
por: Rottman, Martin, et al.
Publicado: (2008)

The role of IL-12, IL-23 and IFN-γ in immunity to viruses
por: Novelli, Francesco, et al.
Publicado: (2004)

Serum IFN-γ and RNAemia temporal profiles as biomarkers of severe COVID-19 in solid organ transplant and immunocompetent patients
por: Salto-Alejandre, Sonsoles, et al.
Publicado: (2023)

Impaired thymic AIRE expression underlies autoantibodies against type I IFNs in humans with inborn errors of the alternative NF-κB pathway
por: Voyer, Tom Le, et al.
Publicado: (2023)

Autoantibodies against type I IFNs in patients with life-threatening COVID-19
por: Bastard, Paul, et al.
Publicado: (2020)

Activation of T Lymphocytes as a Novel Mechanism in Beta1-Adrenergic Receptor Autoantibody-Induced Cardiac Remodeling—Additional Information About TLR9 Involvement
por: Haberland, Annekathrin, et al.
Publicado: (2019)

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1
por: Bastard, Paul, et al.
Publicado: (2021)

Unlocking life-threatening COVID-19 through two types of inborn errors of type I IFNs
por: Casanova, Jean-Laurent, et al.
Publicado: (2023)

Neutrophil to lymphocyte ratio may be predict of mortality in all conditions
por: Balta, S, et al.
Publicado: (2013)

Association between lymphocyte count in bronchoalveolar lavage fluid and mortality
por: Si, Yifu, et al.
Publicado: (2021)

IFITM3‐specific antibody reveals IFN preferences and slow IFN induction of the antiviral factor IFITM3 in humans
por: Wellington, Dannielle, et al.
Publicado: (2020)

Disease-relevant autoantibodies in first episode schizophrenia
por: Zandi, Michael S., et al.
Publicado: (2010)

Prevalence of Islet Autoantibodies in Type 1 Diabetes
por: Dayal, Devi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_dm9femgu3hb2t2rr7acdl7jf9b